MedPath

Chemoreflex Sensitivity in HFpEF

Not yet recruiting
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Diagnostic Test: chemoreflex evaluation
Registration Number
NCT06309537
Lead Sponsor
Istituto Auxologico Italiano
Brief Summary

Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness. Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. However, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities.

Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli, including carbon dioxide produced by the organism during exercise. Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction, and an increased chemoreflex sensitivity has been linked to symptoms, neurohumoral activation, breathing disturbances, and adverse prognosis.

However, the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied.

We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF, and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • diagnosis of symptomatic HFpEF (group 1)
  • diagnosis of asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of PH (group 2)
  • healthy volunteers (group 3)
Read More
Exclusion Criteria
  • breastfeeding or childbearing
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
HFpEFchemoreflex evaluationsymptomatic patients with heart failure with preserved ejection fraction
healthy volonteerschemoreflex evaluation-
asymptomatic PH-LHDchemoreflex evaluationasymptomatic left ventricular diastolic dysfunction with echocardiographic signs of pulmonary hypertension
Primary Outcome Measures
NameTimeMethod
difference in chemoreflex sensitivity between HFpEF and healthy controls5 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ospedale San Luca IRCCS Istituto Auxologico Italiano

🇮🇹

Milan, Italy

© Copyright 2025. All Rights Reserved by MedPath